Der CD38-Antikörper Daratumumab ist bereits zur Monotherapie mehrfach vorbehandelter Myelompatienten zugelassen. Auch zusätzlich zu Lenalidomid/Dexamethason gegeben zeigte er positive Effekte.
↧
Channel:
Latest Results
X
Are you the publisher?
Claim or
contact us
about this channel.
X
0
Channel Details:
- Title: Latest Results
- Channel Number: 61564850
- Language: German
- Registered On: March 14, 2016, 11:03 pm
- Number of Articles: 188
- Latest Snapshot: September 6, 2019, 3:57 pm
- RSS URL: http://link.springer.com/search.rss?facet-creator="barbara kreutzkamp"
- Publisher: http://link.springer.com
- Description: The latest content available from Springer
- Catalog: //available2981.rssing.com/catalog.php?indx=61564850
© 2025 //www.rssing.com